Comments

Kalaris Therapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Kalaris Therapeutics (KLRS) operate in?

Kalaris Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

KLRSNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$3.48

-0.06-1.69%

At close: -

$4.13

0.6518.68%

After Hours: May 16, 8:07 AM EDT

Q1 2025 Earnings were released on Wed May 14th, before the market open

Kalaris Therapeutics (KLRS) Forecast

News Earnings Kalaris Therapeutics (KLRS) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Kalaris Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:KLRS | Benzinga

Explore Kalaris Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for KLRS.

Open	$4.14
Close	$3.48
Volume / Avg.	94.07K / 50.06K
Day Range	$3.47 - $4.14
52 Wk Range	3.10 - 12.90
Market Cap	$77.24M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	20
Short Interest	-
Days to Cover	1.23

Recent News

Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Apr

Buy

Hold

Sell

Strong Sell

Open	$4.14
Close	$3.48
Volume / Avg.	94.07K / 50.06K
Day Range	$3.47 - $4.14
52 Wk Range	3.10 - 12.90
Market Cap	$77.24M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	20
Short Interest	-
Days to Cover	1.23

About Kalaris Therapeutics Inc.

Sector

Health Care

Industry

Biotechnology

Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and com...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Kalaris Therapeutics (KLRS) stock?

You can purchase shares of Kalaris Therapeutics (NASDAQ:KLRS) through any online brokerage.

View our list of the best stock brokerages

Who are Kalaris Therapeutics (KLRS) competitors?

Other companies in Kalaris Therapeutics’s space includes: Serina Therapeutics (AMEX:SER), Skye Bioscience (NASDAQ:SKYE), Citius Oncology (NASDAQ:CTOR), Adaptimmune Therapeutics (NASDAQ:ADAP) and Vistagen Therapeutics (NASDAQ:VTGN).

What is the forecast, or price target, for Kalaris Therapeutics (KLRS) stock?

There is no analysis for Kalaris Therapeutics to provide a consensus price target.

What is the current price for Kalaris Therapeutics (KLRS)?

The stock price for Kalaris Therapeutics (NASDAQ: KLRS) is $4.13 last updated May 16, 2025 at 8:07 AM EDT.

Does Kalaris Therapeutics (KLRS) pay a dividend?

There are no upcoming dividends for Kalaris Therapeutics.

When is Kalaris Therapeutics (NASDAQ:KLRS) reporting earnings?

Kalaris Therapeutics’s Q2 earnings are confirmed for Friday, August 15, 2025.

Is Kalaris Therapeutics (KLRS) going to split?

There is no upcoming split for Kalaris Therapeutics.

What sector and industry does Kalaris Therapeutics (KLRS) operate in?

Kalaris Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.